Article

Cost-utility analysis of genomic profiling in early breast cancer in Colombia

2022-11-10

Abstract excerpt

<h4>Background: </h4> In Colombia, the best strategy to establish indication for adjuvant chemotherapy in early breast cancer (EBC) remains unknown. This study aimed to identify the cost-utility of Oncotype DX™ (ODX) or Mammaprint™ (MMP) tests to establish the necessity of adjuvant chemotherapy. <h4>Methods: </h4>: This study used an adapted decision-analytic model to compare cost and outcomes of care between ODX...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e3c06c99-3305-5ff1-8175-4c7ec736fa9c
DOI: 10.21203/rs.3.rs-2249161/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cost-utility analysis of genomic profiling in early breast cancer in ColombiaDOI 10.21203/rs.3.rs-2249161/v1Read

Cost-Effectiveness Analysis of Genomic Profiling in Early Breast Cancer in ColombiaSemantic proximity Read

Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.Semantic proximity Read

<p class="MDPI12titleori1" style="mso-line-height-alt: 14.0pt;"><span style="mso-bidi-font-size: 18.0pt; mso-bidi-font-weight: bold;">MammaPrint™ Genetic Signature in the Brazilian Population, Analysis of Results and Clinical Outcomes (AGEMA-BRA) – Real World StudySemantic proximity Read

Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.Semantic proximity Read

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trialSemantic proximity Read

A Nomogram for Predicting Mammaprint Results in Women with T1-3N0-1M0 Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor-2-Negative Breast CancerSemantic proximity Read

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china.Semantic proximity Read

Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income CountrySemantic proximity Read

Dihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness AnalysisSemantic proximity Read

[Impact of the 21-gene assay in decision-making during multidisciplinary breast meeting: A French experience].Semantic proximity Read

Using the Cancer Aging and Research Group- Breast Cancer (CARG-BC) predictive model in older adults (OA) with early breast cancer: an external validation studySemantic proximity Read

Estimation of the Stage-Wise Costs of Breast Cancer in Germany Using a Modeling ApproachSemantic proximity Read